Posted: June 23, 2010

MagForce Nanotechnologies AG Successfully Completes Share Placement

(Nanowerk News) MagForce Nanotechnologies AG, a medical technology company listed in the Entry Standard segment of the Frankfurt Stock Exchange, completed a placement of equity with German and international institutional investors. A total of 80,190 newly issued shares were placed, with profit participation rights dating from January 1, 2009, at a price of EUR 42.00 per share. The gross proceeds from this capital increase of EUR 3,367,980.00 will go to the company and are to be used to finance its further growth.
This transaction increases the nominal capital of the company, until now EUR 3,773,198.00 divided into 3,773,198 shares at an imputed nominal value of EUR 1.00, by an amount of EUR 80,190.00, thus bringing its nominal capital to EUR 3,853,388.00. Subscription rights to existing shareholders were excluded by the authority under sec. 6 para. 3 of the company's articles of incorporation (Satzung).
About MagForce Nanotechnologies
MagForce Nanotechnologies AG is a world-leading company in the area of nanotechnology-based cancer treatment. Its patented Nano-Cancer® therapy enables the targeted destruction of tumors using superparamagnetic nanoparticles to generate heat. The nanotechnology from MagForce represents a revolutionary approach to the future successful treatment of solid tumors.
Source: MagForce (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: